TL;DR: A 2026 laboratory study in ACS Omega reported that a laser-induced graphene sensor detected dopamine across a controlled range in artificial human tears, supporting a possible noninvasive biomarker-monitoring route that still needs real human tear testing. Key Findings Laser-induced graphene sensor: Researchers built a small electrochemical device on a plastic film converted into conductive …
TL;DR: A 2026 Nature Communications paper introduced EmulatRx, a multi-agent AI framework that used real-world clinical data to help design target-trial-emulation workflows for acute and chronic diseases, including Alzheimer disease and Parkinson disease examples. Key Findings 20-trial evaluation: Researchers curated 20 clinical trials, with 10 acute-condition trials from MIMIC-IV and 10 chronic-disease trials from INSIGHT. …
TL;DR: A 2026 study in eNeuro used intracranial electroencephalography (EEG), a recording method for brain electrical activity, during deep brain stimulation surgery and found that Parkinson’s disease and essential tremor patients with elevated depression symptoms had weaker corticostriatal alpha-beta reward signaling. Key Findings 30 DBS patients participated: The sample included 14 Parkinson’s disease patients and …
TL;DR: A 2026 study in European Journal of Nuclear Medicine and Molecular Imaging found that semiquantitative [123I]FP-CIT SPECT metrics, especially caudate-to-putamen and sensorimotor-to-limbic ratios, helped distinguish Parkinson’s disease from atypical parkinsonian syndromes, while a random forest classifier remained more useful as decision support than as a standalone diagnosis. Key Findings 706-patient cohort: The study included …
TL;DR: A 2026 narrative review in Molecular Psychiatry argues that depression in Alzheimer’s disease and Parkinson’s disease follows disease-specific brain mechanisms, while standard antidepressant evidence remains weak in these neurodegenerative populations. Key Findings 42% in Alzheimer’s disease: The review cites depressive syndromes affecting about 42% of patients with Alzheimer’s disease and 35% of patients with …
TL;DR: A 2026 study in Nature Communications reported that tubulin redirected Tau and alpha-synuclein condensates toward microtubule-building states, while tubulin loss pushed the same protein system toward toxic oligomers in cell models. Key Findings 36-hour shift: Tau and alpha-synuclein condensates formed stable high-molecular-weight oligomers and Tau:alpha-synuclein heterodimers after aging without tubulin. 10-micromolar tubulin: Adding tubulin …
TL;DR: A 2026 protocol in JMIR Research Protocols describes EXCEL-PD, a randomized trial testing whether 26 weeks of virtually supervised home endurance and resistance exercise is feasible, safe, and biologically informative for people with Parkinson disease. Key Findings Home trial design: EXCEL-PD randomizes 31 planned participants with Parkinson disease to home-based exercise or waitlist usual …
TL;DR: A 2026 medRxiv preprint reported that peripheral blood RNA sequencing separated Parkinson disease from healthy controls and isolated REM sleep behavior disorder more clearly than it separated isolated REM sleep behavior disorder from controls. Key Findings 71 baseline samples: The main analysis included 20 healthy controls, 31 people with isolated REM sleep behavior disorder, …
TL;DR: A 2026 review in Translational Neuroscience summarizes why PINK1 and parkin, two genes linked to early-onset parkinsonism, keep pointing researchers back to mitophagy and autophagy as Parkinson disease mechanisms. Key Findings 18 PARK loci noted: The review frames familial Parkinson genetics as a route into molecular mechanisms, including PARK2 and PARK6. PARK2 encodes parkin: …
TL;DR: A 2026 randomized feasibility trial in Nature Medicine found that gait-synchronized adaptive deep brain stimulation was feasible and safe in 5 people with Parkinson’s disease, with early findings of improved gait symmetry, lower variability, and fewer reported falls than continuous stimulation. Key Findings 5 Parkinson’s patients: The 1-center feasibility trial enrolled people with Parkinson’s …
